| The Company was originally promoted by Mr. A. M. Rao and incorporated
as Emgi Pharmaceuticals & Chemicals Private Limited on September 22,
1988 with Registrar of Companies of Karnataka, Bangalore. On Mr. Rao's
accidental death the Company was put for a sale. In 1989 Mr. Santosh
Varalwar and Mr. Subhash Varalwar acquired Emgi Pharmaceuticals and
Chemicals Limited and commenced manufacturing of Bulk Drugs in 1991.
Both the present promoters are professionals with more than a decade of
experience in Chemicals and Pharmaceutical Industry. The Company was
converted into a Public Limited Company on April 4, 1994. The name of
the Company has been changed to Vivimed Labs Limited on April 22, 1997.
The name of the Company has been changed to incorporate present
Promoter's initials in the Company's name.
The Company's manufacturing Unit is located at Bidar, Karnataka, where
it was originally engaged in the manufacturing of Active Pharmaceutical
Ingredients (APIs) and Bulk Drugs like Ibuprofen etc. However, due to
downward price movement in the products of the Company during 1995, it
gradually moved over to manufacturing Specialty Chemicals and cosmetic
ingredients like Triclosan, Avis etc. catering to global and domestic
markets.
Vivimed started production of Triclosan with a very small capacity of 5
MT p.a, in the year 1999 and increased its capacity to 225 MT p.a. over
a period of next 5 years. The production capacity has been doubled by
adding one more production block in March 2004. The Company currently
employs over 250 personnel including contract laborers.
Vivimed's Turnover has grown from Rs. 751.85 lacs in FY1999 to Rs.
4,042.55 lacs in FY2004 and its Net profit grew from Rs. 15.26 lacs in
FY1999 to Rs. 400.28 lacs in FY2004. The Turnover of the Company for 6
months period ended September 30, 2004 is Rs. 2322.60 Lacs and Net
Profit is Rs.249.24 lacs. As at September 30, 2004, the Networth of the
Company was Rs. 1850.15 lacs.
The Company has ISO 9001:2000 certification for its Quality Management
System related to manufacturing process and marketing aspects. Further,
the Company is in the process of obtaining ISO 14001 certification for
Environmental Management System for which two Audits have already been
completed.
Major events In -the history of the Company is given below:
Year Event
1988 & * Incorporated on September 22, 1988
1989 * Death of original promoter Mr. A. M. Rao
* Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar
1990 * Commenced production of Non-Steroidal Anti-Inflammatory
Drug (NSAID) - IBUPROFEN.
1994 * Diversification and Expansion of Product mix by adding
other APIs viz. Chlorzoxazone (Skeletal disorders),
Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal).
1995 * Diversification into specialty chemicals by production of
Triclosan.
1996 * R&D was commenced with facilities having an integrated
instrumentation for organic synthesis, Microbiology and
pre-formulation studies.
1997 * Process Innovation of Anti-bacterial and clearance of
innovative route of synthesis for Triclosan.
* Grant of patent for VIV-20 (Triclosan) by the Indian
Patents Office.
1998- * Qualified for supply to Unilever's Asian locations after
99 Audit of manufacturing facility by a team of Unilever Plc.
* Triclosan customer base expanded to UK, France, Germany as
well as domestic market;
2002 * Approved by Unilever group Companies in Asian/Middle &
Far East Companies for usage of Enamel Protective Agent
manufactured by the Company in their oral care formulations.
* Developed Anti-fungal for usage in High-end cosmetic and
pre-formulation blends.
* Vivimed emerges as a second chemical Company located outside
USA/Europe to get the US EPA's registration for Triclosan
as 99% ingredient.
* Vivimed's Quality Management System gets ISO 9001:2000
certification.
2003 * Signed Confidential Sale Agreement with HLL for R&D,
scaling up and commercialization of product coded as A123.
* Commencement of EMS Audit for ISO 14001 certification.
2004 * Introduced new products for anti-dandruff and skin care
application
* Triclosan production capacity increased from 225 MT p.a.
to 480 MT p.a.
* Developed novel synthetic process to manufacture a premium
Anti-oxidant and Anti-cancer molecule branded as VINTOX
2005 * The Company has received the State Award for Excellence in
Exports (SSI GOLD) from Karnataka State Government for
excellence in exports
* The Company has received 1 star export house status in 2005.
2009
- Vivimed Labs Ltd has informed BSE that Mr. Y Krishna has been appointed as an Additional Director on the Board of the Company with effect from June 30, 2009 in the Board Meeting of the Company held on June 30, 2009.
2010
- Vivimed Labs Ltd has appointed Mr. Nixon Patel as an Additional Director of the Company with effect from June 28, 2010.
Mr. Nixon Patel has been appointed as an Independent Director on the Board.
2011
-Vivimed Labs Incorporation of Foreign Subsidiaries namely, Vivimed Labs Mauritius Ltd., Mauritius, Vivimed Labs UK Ltd., UK and Vivimed Labs Spain, SL, Spain.
-Vivimed Labs has accquired majority Stake in Octtantis Nobel Labs Private Ltd.
-Vivimed Labs Acquired equity stake in Klar Sehen Pvt. Ltd.
-Vivimed Labs Acquired Uquifa Spain and Uquifa Mexico
2012
-Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona.
-Mr. K. Yugandhar has been appointed as Company Secretary of the company
2013
-Vivimed acquires a US FDA approved formulation manufacturing facility.
-Vivimed are Exhibiting at HPCi - Mumbai.
2014
-Vivimed receives the PIC/S GMP approval for one of its pharmaceuticals manufacturing facilities in Hyderabad.
-Vivimed Labs - Grant of Options under Vivimed Labs ESOS 2010.
2016
-Vivimed's FDF facility in Alathur completed successful USFDA inspection
-Vivimed launch Jarocolr Sapphire Blue
2020
-Vivimed Launches its own brand of favipiravir.
|